Announcement PDF RNS Number : 8084V OptiBiotix Health PLC 11 April 2019 OptiBiotix Health plc ("OptiBiotix" or the "Company") SlimBiome® receives approval from FSSAI in India OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that, further to the previous announcement made on 7 January 2019, it has received a licence from the Food Standards and Safety Authority India ("FSSAI") for its award winning weight management product, SlimBiome® to be manufactured in India. The approval was gained by OptiBiotix's manufacturing partner, Zeon Life Sciences, for both SlimBiome® and SlimBiome® containing products. FSSAI licence approval involves both ingredient and quality verification to ensure the product and manufacturing process is of a high standard and is an essential regulatory requirement to manufacture and distribute food products in India. The licence approval allows Zeon to fulfil orders arising from OptiBiotix's recent visit to India for SlimBiome® and SlimBiome® containing products in its own manufacturing site. This is a strategic step by OptiBiotix to add manufacturing in Asia to the supply chain and extend the market opportunity for its patented award winning weight management product into the fast growing Indian market with an established partner. Zeon include major Indian and international healthcare companies such as Danone, GNC, Decathlon, Sun Pharma and Herbalife amongst its customers and was awarded Nutraceutical Manufacturing Company of the Year in 2017 by The Associated Chambers of Commerce and Industry of India. Stephen O'Hara, CEO of OptiBiotix, commented: "We are really pleased that Zeon has received FSSAI approval to manufacture SlimBiome® in India. This allows them to fulfil partner orders and meet the needs of other partners interested in selling SlimBiome® and SlimBiome® containing products in India. We have been really impressed with the professionalism of Zeon and the speed at which they are creating interest and orders for our products in India. Achieving FSSAI approval so quickly is a significant achievement and is an important step in completing the supply chain to meet the needs of existing and new corporate partners in India and Southern Asia. This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, and white label and own label branded consumer and pharmaceutical products across multiple channels with industry partners from around the world." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. For further information, please contact: OptiBiotix Health plc Stephen O'Hara, Chief Executive Cairn Financial Advisers LLP (NOMAD) Liam Murray / Jo Turner finnCap (Broker) Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) Walbrook PR Ltd Anna Dunphy www.optibiotix.com Contact via Walbrook below Tel: 020 7213 0880 Tel: 020 7220 0500 Tel: 020 7933 8780 or optibiotix@walbrookpr.com Mob: 07876 741 001 About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END MSCZBLFFKZFFBBF